Free Trial

This company has been marked as potentially delisted and may not be actively trading.

IMARA (IMRA) Competitors

IMARA logo

IMRA vs. MOR, GMTX, CALT, ZYME, CMRX, CDMO, SBTX, RVNC, CKPT, and MBX

Should you be buying IMARA stock or one of its competitors? The main competitors of IMARA include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Chimerix (CMRX), Avid Bioservices (CDMO), Silverback Therapeutics (SBTX), Revance Therapeutics (RVNC), Checkpoint Therapeutics (CKPT), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical preparations" industry.

IMARA vs. Its Competitors

IMARA (NASDAQ:IMRA) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

49.3% of IMARA shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 37.3% of IMARA shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

IMARA has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

In the previous week, IMARA and IMARA both had 1 articles in the media. IMARA's average media sentiment score of 0.00 beat MorphoSys' score of -0.71 indicating that IMARA is being referred to more favorably in the media.

Company Overall Sentiment
IMARA Neutral
MorphoSys Negative

IMARA has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. IMARA's return on equity of 2.12% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
IMARAN/A 2.12% 2.00%
MorphoSys -226.79%-694.31%-22.55%

IMARA has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than IMARA, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMARAN/AN/A$1.49M$0.051,008.78
MorphoSys$238.28M11.99-$205.35M-$3.48-5.45

Summary

IMARA beats MorphoSys on 9 of the 11 factors compared between the two stocks.

Get IMARA News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMRA vs. The Competition

MetricIMARAPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.32B$784.70M$5.45B$8.93B
Dividend YieldN/A4.84%5.22%4.01%
P/E Ratio1,008.991.3027.2420.06
Price / SalesN/A230.50426.37117.54
Price / Cash75.2423.4426.2128.59
Price / Book14.666.237.925.56
Net Income$1.49M-$27.94M$3.17B$248.56M

IMARA Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMRA
IMARA
N/A$50.44
+1.0%
N/AN/A$1.32BN/A1,008.9941
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
GMTX
Gemini Therapeutics
N/A$51.68
+0.1%
N/A+17.4%$2.24BN/A-51.6830
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
ZYME
Zymeworks
2.0528 of 5 stars
$12.82
+2.8%
$21.00
+63.8%
+44.5%$891.98M$93.38M-8.55460
CMRX
Chimerix
0.6276 of 5 stars
$8.54
flat
$8.53
-0.1%
N/A$801.09M$212K-9.0990
CDMO
Avid Bioservices
0.6885 of 5 stars
$12.50
+0.1%
$12.25
-2.0%
+68.4%$799.18M$139.91M-5.23320High Trading Volume
SBTX
Silverback Therapeutics
N/A$16.57
+4.9%
N/A+81.5%$597.48MN/A-6.8583High Trading Volume
RVNC
Revance Therapeutics
2.7508 of 5 stars
$3.65
flat
$8.45
+131.5%
N/A$381.02M$234.04M-1.89500
CKPT
Checkpoint Therapeutics
0.423 of 5 stars
$4.26
flat
$4.33
+1.7%
N/A$370.71M$41K-2.3210
MBX
MBX Biosciences
3.0678 of 5 stars
$11.05
+13.6%
$37.50
+239.4%
N/A$369.34MN/A0.0036

Related Companies and Tools


This page (NASDAQ:IMRA) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners